ANI Pharmaceuticals ANIP EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from ANI Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's EBITDA margin?
- ANI Pharmaceuticals (ANIP) reported EBITDA margin of 23.1% in Q1 2026.
- How has ANI Pharmaceuticals's EBITDA margin changed year-over-year?
- ANI Pharmaceuticals's EBITDA margin increased by 132.2% year-over-year, from 9.9% to 23.1%.
- What is the long-term trend for ANI Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's EBITDA margin has grown at a 10.8% compound annual growth rate (CAGR), from 13.7% to 22.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.